HK1025092A1 - (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders - Google Patents
(+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disordersInfo
- Publication number
- HK1025092A1 HK1025092A1 HK00104200A HK00104200A HK1025092A1 HK 1025092 A1 HK1025092 A1 HK 1025092A1 HK 00104200 A HK00104200 A HK 00104200A HK 00104200 A HK00104200 A HK 00104200A HK 1025092 A1 HK1025092 A1 HK 1025092A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- norcisapride
- useful
- mediated disorders
- intestinal disorders
- treating gastro
- Prior art date
Links
- ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparing Plates And Mask In Photomechanical Process (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202161 | 1997-07-11 | ||
EP98200661 | 1998-03-04 | ||
PCT/EP1998/004193 WO1999002496A1 (fr) | 1997-07-11 | 1998-07-07 | (+)-norcisapride utiles pour traiter les troubles a mediation 5-ht3 et 5-ht4 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1025092A1 true HK1025092A1 (en) | 2000-11-03 |
Family
ID=26146686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00104200A HK1025092A1 (en) | 1997-07-11 | 2000-07-08 | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
Country Status (31)
Country | Link |
---|---|
US (2) | US20030060485A1 (fr) |
EP (1) | EP1000029B1 (fr) |
JP (1) | JP3529102B2 (fr) |
KR (1) | KR100358374B1 (fr) |
CN (1) | CN1196681C (fr) |
AT (1) | ATE251139T1 (fr) |
AU (1) | AU757077B2 (fr) |
BG (1) | BG64824B1 (fr) |
BR (1) | BR9811676A (fr) |
CA (1) | CA2292480A1 (fr) |
CO (1) | CO4940432A1 (fr) |
CZ (1) | CZ296212B6 (fr) |
DE (1) | DE69818678T2 (fr) |
DK (1) | DK1000029T3 (fr) |
EA (1) | EA002362B1 (fr) |
EE (1) | EE04491B1 (fr) |
ES (1) | ES2209190T3 (fr) |
HK (1) | HK1025092A1 (fr) |
HR (1) | HRP20000004A2 (fr) |
HU (1) | HUP0003078A3 (fr) |
ID (1) | ID24228A (fr) |
IL (1) | IL133225A (fr) |
MY (1) | MY129130A (fr) |
NO (1) | NO315183B1 (fr) |
NZ (1) | NZ502207A (fr) |
PL (1) | PL190296B1 (fr) |
PT (1) | PT1000029E (fr) |
SK (1) | SK284941B6 (fr) |
TR (1) | TR200000020T2 (fr) |
TW (1) | TW553934B (fr) |
WO (1) | WO1999002496A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147093A (en) | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
JP2003522103A (ja) * | 1998-06-15 | 2003-07-22 | セプラコア インコーポレーテッド | 無呼吸、過食症およびその他の障害を治療するための光学的に純粋な(−)−ノルシスアプリドの使用 |
EP1089733B1 (fr) | 1998-06-15 | 2005-03-23 | Sepracor Inc. | Utilisation du (+) norcisapride optiquement pur pour traiter le syndrome du colon irritable |
EP1464333A3 (fr) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Procedes permettant de traiter l'apnee, la boulimie et d'autres troubles au moyen du norcisapride (-) optiquement pur |
EP1468685A3 (fr) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Procedes permettant de traiter l'apnee, la boulimie et d'autres troubles au moyen du norcisapride (+) optiquement pur |
US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
EP1200090B1 (fr) * | 1999-08-03 | 2013-09-11 | ICOS Corporation | Formulation pharmaceutique à base d'une béta-carboline et son utilisation pour traiter le dysfonctionnement sexuel |
AU2001275326C1 (en) * | 2000-06-07 | 2006-09-21 | Aryx Therapeutics | Treatment of gastroesophageal reflux disease using piperidine derivatives |
WO2002041918A2 (fr) * | 2000-11-24 | 2002-05-30 | Janssen Pharmaceutica N.V. | Utilisation d'une combinaison triple contenant un antagoniste 5ht3, un agoniste 5ht4 et un laxatif facilitant le lavement intestinal |
AU2002356418A1 (en) * | 2001-10-08 | 2003-04-22 | Sun Pharmaceutical Industries Limited | An antispasmodic agent spaced drug delivery system |
JP2003342186A (ja) * | 2002-05-24 | 2003-12-03 | Taisho Pharmaceut Co Ltd | 鼻炎用内服液剤組成物 |
US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
US8138204B2 (en) | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
WO2005068461A1 (fr) | 2004-01-07 | 2005-07-28 | Aryx Therapeutics | Composes stereo-isomeres et methodes de traitement de troubles gastro-intestinaux et du systeme nerveux central |
US20060247180A1 (en) * | 2005-04-29 | 2006-11-02 | Bergey James L | Purgative composition and uses thereof |
CA2620379C (fr) | 2005-08-31 | 2015-02-24 | Aryx Therapeutics, Inc. | Methodes synthetiques et intermediaires de composes stereoisomeres utiles dans le traitement des troubles gastro-intestinaux et du systeme nerveux central |
KR20100026641A (ko) * | 2008-09-01 | 2010-03-10 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
JP7203083B2 (ja) * | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
EP3820468A4 (fr) * | 2018-07-11 | 2022-03-23 | Duke University | Utilisation de 5-hydroxytryptophane à libération prolongée dans le traitement de troubles gastro-intestinaux |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1183847A (fr) * | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide; derives |
US4820715A (en) * | 1984-06-28 | 1989-04-11 | Bristol-Myers Company | Anti-emetic quinuclidinyl benzamides |
NZ225152A (en) * | 1987-07-17 | 1990-04-26 | Janssen Pharmaceutica Nv | Heterocyclically substituted piperidinyl benzamides as pharmaceuticals |
US4975439A (en) * | 1987-09-25 | 1990-12-04 | Janssen Pharmaceutical N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
IL89848A (en) * | 1988-04-07 | 1997-08-14 | Sepracor | Chiral ester derivatives |
TW213460B (fr) * | 1991-02-15 | 1993-09-21 | Hokuriku Pharmaceutical | |
TW294595B (fr) * | 1992-11-20 | 1997-01-01 | Janssen Pharmaceutica Nv | |
FR2717174B1 (fr) * | 1994-03-14 | 1996-05-31 | Sanofi Sa | Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes. |
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
-
1998
- 1998-07-07 JP JP50812899A patent/JP3529102B2/ja not_active Expired - Fee Related
- 1998-07-07 HU HU0003078A patent/HUP0003078A3/hu unknown
- 1998-07-07 CN CNB988069563A patent/CN1196681C/zh not_active Expired - Fee Related
- 1998-07-07 TR TR2000/00020T patent/TR200000020T2/xx unknown
- 1998-07-07 EE EEP200000014A patent/EE04491B1/xx not_active IP Right Cessation
- 1998-07-07 WO PCT/EP1998/004193 patent/WO1999002496A1/fr active IP Right Grant
- 1998-07-07 KR KR1019997012056A patent/KR100358374B1/ko not_active IP Right Cessation
- 1998-07-07 PT PT98940159T patent/PT1000029E/pt unknown
- 1998-07-07 ID IDW20000033A patent/ID24228A/id unknown
- 1998-07-07 AU AU88575/98A patent/AU757077B2/en not_active Ceased
- 1998-07-07 IL IL13322598A patent/IL133225A/xx not_active IP Right Cessation
- 1998-07-07 SK SK1829-99A patent/SK284941B6/sk unknown
- 1998-07-07 DK DK98940159T patent/DK1000029T3/da active
- 1998-07-07 BR BR9811676-2A patent/BR9811676A/pt not_active Application Discontinuation
- 1998-07-07 AT AT98940159T patent/ATE251139T1/de not_active IP Right Cessation
- 1998-07-07 EP EP98940159A patent/EP1000029B1/fr not_active Expired - Lifetime
- 1998-07-07 DE DE69818678T patent/DE69818678T2/de not_active Expired - Fee Related
- 1998-07-07 CZ CZ0461799A patent/CZ296212B6/cs not_active IP Right Cessation
- 1998-07-07 EA EA200000057A patent/EA002362B1/ru not_active IP Right Cessation
- 1998-07-07 PL PL98337648A patent/PL190296B1/pl unknown
- 1998-07-07 CA CA002292480A patent/CA2292480A1/fr not_active Abandoned
- 1998-07-07 NZ NZ502207A patent/NZ502207A/en unknown
- 1998-07-07 ES ES98940159T patent/ES2209190T3/es not_active Expired - Lifetime
- 1998-07-08 MY MYPI98003108A patent/MY129130A/en unknown
- 1998-07-08 TW TW087111013A patent/TW553934B/zh not_active IP Right Cessation
- 1998-07-09 CO CO98038980A patent/CO4940432A1/es unknown
-
1999
- 1999-11-30 BG BG103934A patent/BG64824B1/bg unknown
-
2000
- 2000-01-05 HR HR20000004A patent/HRP20000004A2/xx not_active Application Discontinuation
- 2000-01-07 NO NO20000093A patent/NO315183B1/no unknown
- 2000-07-08 HK HK00104200A patent/HK1025092A1/xx not_active IP Right Cessation
-
2002
- 2002-09-16 US US10/244,365 patent/US20030060485A1/en not_active Abandoned
-
2004
- 2004-03-23 US US10/807,035 patent/US20040176414A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000004A2 (en) | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders | |
MX9707980A (es) | Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos. | |
BG102999A (en) | New 2,3-diasubstituted-4-(3h)-quinazolinons | |
UA29476C2 (uk) | Трансдермальна терапевтична система, що містить естрадіол | |
CA2272584A1 (fr) | Nouveaux derives de pyrazole substitues pour le traitement de maladies cardio-vasculaires | |
RO115522B1 (ro) | Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament | |
UA27749C2 (uk) | Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі | |
HU9601857D0 (en) | New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them | |
ZA961074B (en) | Chiral Methylphenyloxazolidinones. | |
AU2102497A (en) | Resolution of threo-methylphenidate | |
GR3024592T3 (en) | Process for preparing and resolving 2-phenyl-3-aminopiperidine | |
CA2282279A1 (fr) | Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central | |
UA41353C2 (uk) | Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність | |
CA2296560A1 (fr) | Derives d'acides amines pour le traitement des accidents cerebrovasculaires | |
ZA973156B (en) | Process for the production of enantiomerically-pure azetidine-2-carboxylic acid. | |
IL122708A0 (en) | Process for the production of enantiomerically-pure azetidine-2-carboxylic acid | |
ZA976854B (en) | Treatment of psychotic disorders. | |
EP0804186A4 (fr) | Composes alkaloides du type indole-diterpene | |
MY101747A (en) | Dihydroorotic acids derivative, processes for preparing the same | |
PL352119A1 (en) | Derivatives of aminotetraline for treatment of cardiovascular diseases | |
HUT77439A (hu) | Új eljárás ranitidin előállítására | |
MX9604692A (es) | Derivados de quinoxalina para el tratamiento de tinnitus. | |
JO2127B1 (en) | How to prevent asthma | |
JO1720B1 (en) | Heterocyclic derivatives | |
SI0906255T1 (en) | Process for the production of enantiomerically-pure azetidine-2-carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20080707 |